ATAI Life Sciences

ATAI

Market cap $1.28B

Needham on Monday initiated coverage on Atai Life Sciences NV (NASDAQ:ATAI), a clinical-stage biopharmaceutical company focused on developing treatments for mental health.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) chief scientific officer Glenn Short spoke with Proactive about the company's recent NIH grant and its innovative discovery program targeting opioid use disorder (OUD).  Short explained that the NIH grant review process is “highly competitive,” with independent experts assessing the novelty and potential impact of atai's work.

Atai Life Sciences N.V. has surged >275% YTD, driven by promising psychedelic drug candidates targeting treatment-resistant depression and other mental health disorders. ATAI's lead asset, BPL-003, shows strong, durable efficacy in early trials, potentially surpassing Spravato, but regulatory and scheduling hurdles remain significant risks. Despite a tight cash position and upcoming milestones, ATAI's valuation may be fair or slightly overvalued, with major catalysts like Phase 2b/3 data and FDA discussions ahead.

Atai Life Sciences (ATAI 14.96%), an ambitious biotech that targets mental health disorders, was a hot item among equity investors Tuesday. The company saw its share price rise by just under 15% that day, thanks to quite positive results from a clinical trial of an investigational drug.

Atai Life Sciences ATAI and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD).

Shares in atai Life Sciences (NASDAQ:ATAI, ETR:9VC) rose 10% on Tuesday after the company and its UK partner Beckley Psytech reported encouraging mid-stage trial results for their experimental nasal spray treatment for depression. The therapy, BPL-003, is a formulation of mebufotenin benzoate delivered via nasal spray.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) and Beckley Psytech said Tuesday that their experimental nasal spray for depression showed promising results in a mid-stage clinical trial, bolstering hopes for a new treatment option in an area where existing therapies often fall short. The drug, known as BPL-003, is a formulation of mebufotenin benzoate delivered through a nasal spray.

NEW YORK and AMSTERDAM and OXFORD, United Kingdom, Sept. 23, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, and Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biopharmaceutical company pioneering the next generation of mental health treatments, today announced positive data from a proof-of-concept study investigating a two-dose induction regimen of BPL-003 (intranasal mebufotenin benzoate), in patients with treatment-resistant depression (TRD).

Here is how atai Life Sciences N.V. (ATAI) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has been awarded a grant of up to $11.4 million from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to advance its work on novel therapies for opioid use disorder (OUD). The company said that the five-year UG3/UH3 grant will support optimization and early-stage development of atai's 5-HT2A/2C receptor agonists, which are designed to retain therapeutic activity without hallucinogenic effects.